INTRODUCTIONConsumption of omega-3 fatty acids can alter the inflammatory response in diabetic patients. This study aimed to determine the effects of omega-3 fatty acid supplementation on the serum levels of C-reactive protein (CRP), interleukin (IL)-2 and tumour necrosis factor-alpha (TNF-α) in type 2 diabetes mellitus patients.

METHODSA randomised, double-blind, placebo-controlled clinical trial was conducted on 84 subjects aged 45-85 years with at least a two-year history of type 2 diabetes mellitus. Participants were randomly assigned to the treatment or control group. Each subject in the treatment group received three omega-3 capsules per day (eicosapentaenoic acid 1,548 mg; docosahexaenoic acid 828 mg; other omega-3 fatty acids 338 mg), while each subject in the control group received three placebo capsules (sunflower oil 2,100 mg) for a period of eight weeks. At the beginning of the study and post intervention, fasting blood samples were taken and serum concentrations of IL-2, TNF-α and CRP were assessed and compared.

RESULTSSerum IL-2 and TNF-α levels were significantly reduced in the treatment group compared to the controls (p < 0.01). There was no significant change in serum CRP levels.

CONCLUSIONShort-term omega-3 fatty acid supplementation (3 g/day for eight weeks) can decrease the serum levels of TNF-α and IL-2 in diabetic patients, with no change in CRP levels. Consumption of omega-3 fatty acid supplements is highly recommended to alleviate inflammation caused by type 2 diabetes mellitus.

Aged ; Aged, 80 and over ; Biomarkers ; blood ; C-Reactive Protein ; drug effects ; metabolism ; Diabetes Mellitus, Type 2 ; blood ; drug therapy ; immunology ; Dietary Supplements ; Double-Blind Method ; Fatty Acids, Omega-3 ; pharmacology ; therapeutic use ; Female ; Humans ; Inflammation ; blood ; prevention & control ; Interleukin-2 ; blood ; Male ; Middle Aged ; Tumor Necrosis Factor-alpha ; blood ; drug effects

Objectives: Polycystic ovary syndrome (PCOS) is a common, heterogeneous clinical syndrome affecting women. Investigating oxidative stress in women is crucial, as it is linked to insulin resistance and endothelial dysfunction. Chlorogenic acid, a bioactive component found in greencoffee, has numerous documented health benefits. This study aimed to assess the beneficial effects of green coffee consumption on paraoxonase-1 (PON-1) activity and malondialdehyde (MDA) levelsin women with PCOS. Methods: This study was a double-blind randomized clinical trial that included 44 patients withPCOS. Participants were randomly assigned to either the intervention or control group. For 6 weeks, the intervention group (n = 22) received 400 mg of green coffee supplements, while the control group (n = 22) received 400 mg of a starch-based placebo. Anthropometric indices, dietary assessments, and physical activity levels were evaluated before and after the 6-week intervention period. Additionally, blood samples were collected for laboratory analysis. Results: Supplementation with green coffee increased PON-1 levels by 3.5 units, a significant finding (p = 0.038). Additionally, the intake of green coffee supplements significantly reduced blood cholesterol levels by 18.8 units (p = 0.013) and triglyceride levels by 6.1 units (p = 0.053). However, no significant differences were observed in the levels of MDA, high-density lipoprotein, low-densitylipoprotein, fasting blood sugar, insulin, or homeostatic model assessment of insulin resistance as a result of the intervention. Conclusion Supplementation with green coffee alters PON-1 activity and cholesterol levels in women with PCOS. However, it has no significant impact on MDA levels or glycemic status.

Objectives: Polycystic ovary syndrome (PCOS) is a common, heterogeneous clinical syndrome affecting women. Investigating oxidative stress in women is crucial, as it is linked to insulin resistance and endothelial dysfunction. Chlorogenic acid, a bioactive component found in greencoffee, has numerous documented health benefits. This study aimed to assess the beneficial effects of green coffee consumption on paraoxonase-1 (PON-1) activity and malondialdehyde (MDA) levelsin women with PCOS. Methods: This study was a double-blind randomized clinical trial that included 44 patients withPCOS. Participants were randomly assigned to either the intervention or control group. For 6 weeks, the intervention group (n = 22) received 400 mg of green coffee supplements, while the control group (n = 22) received 400 mg of a starch-based placebo. Anthropometric indices, dietary assessments, and physical activity levels were evaluated before and after the 6-week intervention period. Additionally, blood samples were collected for laboratory analysis. Results: Supplementation with green coffee increased PON-1 levels by 3.5 units, a significant finding (p = 0.038). Additionally, the intake of green coffee supplements significantly reduced blood cholesterol levels by 18.8 units (p = 0.013) and triglyceride levels by 6.1 units (p = 0.053). However, no significant differences were observed in the levels of MDA, high-density lipoprotein, low-densitylipoprotein, fasting blood sugar, insulin, or homeostatic model assessment of insulin resistance as a result of the intervention. Conclusion Supplementation with green coffee alters PON-1 activity and cholesterol levels in women with PCOS. However, it has no significant impact on MDA levels or glycemic status.

Objectives: Polycystic ovary syndrome (PCOS) is a common, heterogeneous clinical syndrome affecting women. Investigating oxidative stress in women is crucial, as it is linked to insulin resistance and endothelial dysfunction. Chlorogenic acid, a bioactive component found in greencoffee, has numerous documented health benefits. This study aimed to assess the beneficial effects of green coffee consumption on paraoxonase-1 (PON-1) activity and malondialdehyde (MDA) levelsin women with PCOS. Methods: This study was a double-blind randomized clinical trial that included 44 patients withPCOS. Participants were randomly assigned to either the intervention or control group. For 6 weeks, the intervention group (n = 22) received 400 mg of green coffee supplements, while the control group (n = 22) received 400 mg of a starch-based placebo. Anthropometric indices, dietary assessments, and physical activity levels were evaluated before and after the 6-week intervention period. Additionally, blood samples were collected for laboratory analysis. Results: Supplementation with green coffee increased PON-1 levels by 3.5 units, a significant finding (p = 0.038). Additionally, the intake of green coffee supplements significantly reduced blood cholesterol levels by 18.8 units (p = 0.013) and triglyceride levels by 6.1 units (p = 0.053). However, no significant differences were observed in the levels of MDA, high-density lipoprotein, low-densitylipoprotein, fasting blood sugar, insulin, or homeostatic model assessment of insulin resistance as a result of the intervention. Conclusion Supplementation with green coffee alters PON-1 activity and cholesterol levels in women with PCOS. However, it has no significant impact on MDA levels or glycemic status.

Objectives: Polycystic ovary syndrome (PCOS) is a common, heterogeneous clinical syndrome affecting women. Investigating oxidative stress in women is crucial, as it is linked to insulin resistance and endothelial dysfunction. Chlorogenic acid, a bioactive component found in greencoffee, has numerous documented health benefits. This study aimed to assess the beneficial effects of green coffee consumption on paraoxonase-1 (PON-1) activity and malondialdehyde (MDA) levelsin women with PCOS. Methods: This study was a double-blind randomized clinical trial that included 44 patients withPCOS. Participants were randomly assigned to either the intervention or control group. For 6 weeks, the intervention group (n = 22) received 400 mg of green coffee supplements, while the control group (n = 22) received 400 mg of a starch-based placebo. Anthropometric indices, dietary assessments, and physical activity levels were evaluated before and after the 6-week intervention period. Additionally, blood samples were collected for laboratory analysis. Results: Supplementation with green coffee increased PON-1 levels by 3.5 units, a significant finding (p = 0.038). Additionally, the intake of green coffee supplements significantly reduced blood cholesterol levels by 18.8 units (p = 0.013) and triglyceride levels by 6.1 units (p = 0.053). However, no significant differences were observed in the levels of MDA, high-density lipoprotein, low-densitylipoprotein, fasting blood sugar, insulin, or homeostatic model assessment of insulin resistance as a result of the intervention. Conclusion Supplementation with green coffee alters PON-1 activity and cholesterol levels in women with PCOS. However, it has no significant impact on MDA levels or glycemic status.

Objectives: Polycystic ovary syndrome (PCOS) is a common, heterogeneous clinical syndrome affecting women. Investigating oxidative stress in women is crucial, as it is linked to insulin resistance and endothelial dysfunction. Chlorogenic acid, a bioactive component found in greencoffee, has numerous documented health benefits. This study aimed to assess the beneficial effects of green coffee consumption on paraoxonase-1 (PON-1) activity and malondialdehyde (MDA) levelsin women with PCOS. Methods: This study was a double-blind randomized clinical trial that included 44 patients withPCOS. Participants were randomly assigned to either the intervention or control group. For 6 weeks, the intervention group (n = 22) received 400 mg of green coffee supplements, while the control group (n = 22) received 400 mg of a starch-based placebo. Anthropometric indices, dietary assessments, and physical activity levels were evaluated before and after the 6-week intervention period. Additionally, blood samples were collected for laboratory analysis. Results: Supplementation with green coffee increased PON-1 levels by 3.5 units, a significant finding (p = 0.038). Additionally, the intake of green coffee supplements significantly reduced blood cholesterol levels by 18.8 units (p = 0.013) and triglyceride levels by 6.1 units (p = 0.053). However, no significant differences were observed in the levels of MDA, high-density lipoprotein, low-densitylipoprotein, fasting blood sugar, insulin, or homeostatic model assessment of insulin resistance as a result of the intervention. Conclusion Supplementation with green coffee alters PON-1 activity and cholesterol levels in women with PCOS. However, it has no significant impact on MDA levels or glycemic status.